Recent advances in the structural molecular biology of Ets transcription factors: interactions, interfaces and inhibition. Read more about Recent advances in the structural molecular biology of Ets transcription factors: interactions, interfaces and inhibition.
The Structural Basis of PI3K Cancer Mutations: From Mechanism to Therapy. Read more about The Structural Basis of PI3K Cancer Mutations: From Mechanism to Therapy.
The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface. Read more about The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.
Structural characterization of a new N-substituted pantothenamide bound to pantothenate kinases from Klebsiella pneumonia and Staphylococcus aureus. Read more about Structural characterization of a new N-substituted pantothenamide bound to pantothenate kinases from Klebsiella pneumonia and Staphylococcus aureus.
EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Read more about EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor. Read more about Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor.
Mutation or knock-down of 17β-hydroxysteroid dehydrogenase type 10 cause loss of MRPP1 and impaired processing of mitochondrial heavy strand transcripts. Read more about Mutation or knock-down of 17β-hydroxysteroid dehydrogenase type 10 cause loss of MRPP1 and impaired processing of mitochondrial heavy strand transcripts.
The roles of Jumonji-type oxygenases in human disease. Read more about The roles of Jumonji-type oxygenases in human disease.
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Read more about Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
